Clinical Trials in Washington

Showing 4261-4280 of 9,462 trials

CGMIS 48-hour Feasibility Study

NCT05562206

This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.

Type1diabetes

Pacific Diabetes Technologies20 participantsStarted Aug 2022

Renton, Washington, United States

COMPLETEDPhase 336 miles

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022

An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.

Major Depressive DisorderTreatment Resistant DepressionDepression

Axsome Therapeutics, Inc.876 participantsStarted Jul 2019

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Bellflower, California, United States +48 more locations

CGMIS 48-hour Feasibility Study

Open-Label Safety Study of AXS-05 in Subjects With Depression

Find Trials by Condition in Washington

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

The Impact of "First-Line" Rhythm Therapy on AF Progression

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC